Catalent Inc (0C8.SG)
| Previous close | 54.14 |
| Open | 54.38 |
| Bid | 53.81 x 300000 |
| Ask | 53.95 x 300000 |
| Day's range | 53.80 - 54.38 |
| 52-week range | 29.75 - 56.20 |
| Volume | |
| Avg. volume | 4 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
SOMERSET, N.J., August 29, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the fourth quarter of fiscal 2024, which ended June 30, 2024.
- Business Wire
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
SOMERSET, N.J., July 16, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany. The Schorndorf site, Catalent’s flagship European facility, provides comprehensive clinical supply services, including packaging, storage and distribution.
- Business Wire
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J., May 29, 2024--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the "Special Meeting") held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S ("Novo Holdings") will acquire all outstanding shares of Catalent for $63.50 per share in cash (the "Merger").
